Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 26, 2005. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under Disclosure Rule 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction notifications.
Material Changes
No material changes to financial performance or operations are reported in this filing. The only reported activity is an increase in shareholdings by specific individuals following the re-investment of dividends paid on July 7, 2005.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It is a routine disclosure of insider share purchases.
Important Facts for Investors
- Transaction Type: Increase in Ordinary Shares via dividend re-investment.
- Share Price: GBP 13.73 per share.
- Participants: Mr R Bondy (189 shares), Mr M Dunoyer (70 shares), Dr D Pulman (108 shares), Mr A Witty (66 shares), and Mrs J Younger (191 shares).
- Dividend Date: July 7, 2005.
- Notification Date: July 26, 2005.